Skip to content

Impact of iloprost on early graft viability after liver transplantation

Impact of iloprost on early graft viability after liver transplantation: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN95672167
Enrollment
80
Registered
2008-10-09
Start date
2006-09-01
Completion date
Unknown
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver transplantation Injury, Occupational Diseases, Poisoning Failure and rejection of transplanted organs and tissues

Interventions

A prospective, randomised, single-center study. Patients of the treatment group received 1 ng/kg body weight /min iloprost (BayerVital AG Berlin, Germany), systemically administered for 7 days post-li

Sponsors

University Hospital of Jena (Universitätsklinikum Jena) (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years, either gender 2. Full size orthotop liver transplantation

Exclusion criteria

Exclusion criteria: 1. Circulatory instability 2. Noradrenaline doses >0.5 µg/kg body weight/min 3. Pregnancy 4. Known intolerance of iloprost

Design outcomes

Primary

MeasureTime frame
Incidence of primary graft dysfunction within 48 hours postoperatively.

Secondary

MeasureTime frame
1. Rate of re-transplantation caused by initial graft non-function within 48 hours postoperatively 2. Time of hospitalisation (duration of follow-up depends on the circumstances of each patient) 3. Length of stay in intensive care unit (duration of follow-up depends on the circumstances of each patient) 4. Rate of complications due to biliary tract lesions within 1-year follow-up

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 28, 2026